Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe O Szapary

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
American Heart Journal|August 17, 2004
The triglyceride-high-density lipoprotein axis: an important target of therapy?Philippe O Szapary, Daniel J Rader
Archives of Internal Medicine|January 28, 2003
The new definition of myocardial infarctionCarmen E Guerra, Philippe O Szapary
Nutrition Reviews|March 5, 2004
Flaxseed and cardiovascular riskLeAnne T Bloedon, Philippe O Szapary
Journal of Pharmacokinetics and Pharmacodynamics|February 18, 2011
Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasisChuanpu Hu, Philippe O Szapary, Newman Yeilding, et al.
Current Cardiology Reports|October 16, 2003
Physical activity and its effects on lipidsPhilippe O Szapary, LeAnne T Bloedon, Gary D Foster
Journal of Pharmacokinetics and Pharmacodynamics|July 21, 2014
Latent variable indirect response joint modeling of a continuous and a categorical clinical endpointChuanpu Hu, Philippe O Szapary, Alan M Mendelsohn, et al.
Diabetes Care|January 10, 2009
Antidiabetic action of bezafibrate in a large observational databaseJames H Flory, Susan Ellenberg, Philippe O Szapary, et al.
Journal of the American College of Nutrition|March 14, 2007
Flaxseed reduces plasma cholesterol levels in hypercholesterolemic mouse modelsMichael A Pellizzon, Jeffery T Billheimer, Leanne T Bloedon, et al.
Journal of Drugs in Dermatology : JDD|February 5, 2013
Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)Xuejun Zhu, Min Zheng, Michael Song, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 18, 2017
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's diseaseChuanpu Hu, Omoniyi J Adedokun, Yang Chen, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
American Heart Journal|August 17, 2004
The triglyceride-high-density lipoprotein axis: an important target of therapy?Philippe O Szapary, Daniel J Rader
Archives of Internal Medicine|January 28, 2003
The new definition of myocardial infarctionCarmen E Guerra, Philippe O Szapary
Nutrition Reviews|March 5, 2004
Flaxseed and cardiovascular riskLeAnne T Bloedon, Philippe O Szapary
Journal of Pharmacokinetics and Pharmacodynamics|February 18, 2011
Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasisChuanpu Hu, Philippe O Szapary, Newman Yeilding, et al.
Current Cardiology Reports|October 16, 2003
Physical activity and its effects on lipidsPhilippe O Szapary, LeAnne T Bloedon, Gary D Foster
Journal of Pharmacokinetics and Pharmacodynamics|July 21, 2014
Latent variable indirect response joint modeling of a continuous and a categorical clinical endpointChuanpu Hu, Philippe O Szapary, Alan M Mendelsohn, et al.
Diabetes Care|January 10, 2009
Antidiabetic action of bezafibrate in a large observational databaseJames H Flory, Susan Ellenberg, Philippe O Szapary, et al.
Journal of the American College of Nutrition|March 14, 2007
Flaxseed reduces plasma cholesterol levels in hypercholesterolemic mouse modelsMichael A Pellizzon, Jeffery T Billheimer, Leanne T Bloedon, et al.
Journal of Drugs in Dermatology : JDD|February 5, 2013
Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)Xuejun Zhu, Min Zheng, Michael Song, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 18, 2017
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's diseaseChuanpu Hu, Omoniyi J Adedokun, Yang Chen, et al.
Pageof 3